General Archive

Home » Chronic respiratory infection » Page 3
  • LifeArc scientist selecting samples in orange-capped vials from a grey, multi-well plate for testing.
    News releases

    LifeArc plans two major funding calls to boost translational research in rare disease & lung health in cystic fibrosis

    The calls are part of our wider £100m programme to support scientific innovation for people living with cystic fibrosis.

    Read more

  • News releases

    £3m fund to accelerate development of new CF therapies

    Collaborative funding to drug discovery innovators to accelerate new treatments for people with cystic fibrosis.

    Read more

  • Woman uses a nebulizer at home.
    News releases

    LifeArc partners with EMBARC to improve healthcare for people living with bronchiectasis

    Three-year partnership to improve healthcare for thousands of people across Europe living with bronchiectasis.

    Read more

  • Person using nebulizer and inhaler for the treatment
    News releases

    LifeArc announces £10m funding call for new chronic respiratory infection therapies

    First major funding call announced as part of our £100m Chronic Respiratory Infection Translational Challenge

    Read more

  • Microscopic view of lung tissue with congestion as shown by the red blood cells in the walls of the alveoli. Pneumonia.
    News releases

    £100m programme to transform care for people living with chronic lung conditions

    More than 300,000 people in the UK are living with bronchiectasis and more than 10,000 have been diagnosed with cystic…

    Read more

  • Sammie Read, who has a chronic respiratory infection, with the at-home monitoring equipment.
    News releases

    LifeArc funds home monitoring trials for people with chronic respiratory conditions

    Trials will examine the impact of home monitoring and machine learning decision support algorithms for people with CF and bronchiectasis.

    Read more

  • Articles

    AbbVie acquires LifeArc portfolio company DJS Antibodies

    AbbVie will pay DJS shareholders approximately $255 million in cash at closing for the acquisition of DJS

    Read more

  • Scientist in the antibody humanisation lab at LifeArc
    News releases

    Promising new asthma medicine ready to enter early clinical trials

    LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe…

    Read more

  • Scientists at University of Edinburgh
    News releases

    Pandemic Science Hub to develop better drugs to fight lung disease

    New, multi-million pound research programme at the University of Edinburgh will develop treatments for lung infections

    Read more

  • Scientist wearing PPE in lab, carrying out an experiment

    Rising to the challenge of COVID-19

    While the development of COVID-19 vaccines has garnered much attention, scientists have also been looking at repurposed medicines as an…

    Read more

  • image of COVID-19

    How to kill a virus: LifeArc’s role in shaping the UK’s COVID-19 response

    In 2020 the UK Government, supported by UK Research and Innovation and the National Institute for Health and Research, launched…

    Read more

  • LifeArc scientists play pivotal role in the search for a COVID-19 antibody therapy

    While much attention in the race for treatments for Covid-19 has been on the development of new vaccines, scientists have…

    Read more